Becotatug Vedotin: First Approval

DeclarationsAuthorship and Conflict of interest During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.Additional information about this Adis Drug Review can be found here.AbstractBecotatug vedotin (MEIYOUHENG®), an antibody drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR), is being developed by Lepu Biopharma for the treatment of various cancers. In October 2025, becotatug vedotin received its first approval in China for the treatment of adult patients with recurrent/metastatic nasopharyngeal carcinoma who have failed at least two lines of systemic chemotherapy and programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) inhibitor therapy. This article summarizes the milestones in the development of becotatug vedotin leading to this first approval for nasopharyngeal cancer.© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2026